Wednesday, 30 September 2026Updated 6m ago
← Top stories
Expansion▲ Bullish for Sai Life Sciences

This multibagger pharma stock is down 10% from record high—CFO reveals growth plan

1 source · first seen 11:15 30 Sept · updated 11:15 30 Sept

The brief

Written from 1 report · check the source before you trade
  • Sai Life Sciences CFO Sivaramakrishnan Chittor said progress continues in the China Plus One opportunity
  • China Plus One demand could benefit Indian pharmaceutical services companies, including Sai Life Sciences

Tags on this story

Pick a tag to see all its stories
Sai Life Sciences₹1,559.90 · 1 todayPharma and healthcare46 todayChina52 today

Linked by the tag Pharma and healthcare

144 stories this week
  1. 29 SeptSC flags a costly dose of markups, asks for 16% cap on essential medsLegal · 2 sources · Supreme Court asks Centre why essential medicines could not have a 16% MRP cap
  2. 29 SeptExpanding innovative portfolio may drive gains for Sun Pharma stockBroker call · 1 source · Lerodalcibep licensing, US portfolio growth and tariff relief are cited as potential stock drivers
  3. 29 SeptSun Pharma Plans Rs 10,000 Crore Rupee Debt Sale To Refinance Organon Deal: ReportFunding and debt · 2 sources · Sun Pharma plans a ₹10,000 crore bond sale to refinance its Organon deal
  4. 29 SeptSun Pharma plans $1 billion local debt sale for loan takeout, sources sayFunding and debt · 3 sources · Sun Pharma plans to raise about ₹10,000 crore through rupee-denominated bonds
  5. 29 SeptZydus hits 52-week high, can the optimism continue?Market move · 1 source · Zydus Lifesciences has gained 32% in 2026
All Pharma and healthcare stories →

Read the reports

1 report · earliest 11:15
CNBC-TV18This multibagger pharma stock is down 10% from record high—CFO reveals growth plan11:15